SGLT2 inhibitors for type 2 diabetes: how efficient are they in the analytic and anthropometric control?

Authors

  • David Paraíso Saldanha Clínica Universitária de Medicina Geral e Familiar, Faculdade de Medicina da Universidade de Coimbra. Coimbra, Portugal | Centro de Estudos e Investigação em Saúde da Universidade de Coimbra (CEISUC). Coimbra, Portugal. https://orcid.org/0000-0002-6309-6826
  • Luiz Miguel Santiago Faculdade de Medicina da Universidade de Coimbra Clínica Universitária de Medicina Geral e Familiar da Faculdade de Medicina da Universidade de Coimbra USF Topázio, ACES Baixo Mondego http://orcid.org/0000-0002-9343-2827
  • Barbara Oliveiros Laboratório de Bioestatística e Informática Médica, iCBR – Coimbra Institute for Clinical and Biomedical Research, Faculdade de Medicina da Universidade de Coimbra. Coimbra, Portugal.
  • João Pestana USF Topázio, ACeS Baixo Mondego. Coimbra, Portugal. https://orcid.org/0000-0003-3522-8809

DOI:

https://doi.org/10.32385/rpmgf.v40i1.13769

Keywords:

Type 2 diabetes mellitus, SGLT2 inhibitors, Analytic control, Anthropometric control

Abstract

Objective: To ascertain the five-year effectiveness of SGLT2 inhibitor (iSGLT2) medicines on Type 2 Diabetes Mellitus Persons (T2DMP) on haemoglobin (HbA1c), body mass index (BMI) and abdominal perimeter (AP) values.

Methods: Observational multicentric retrospective cohort study, in 2022, analysing data provided by the Regional Health Administration Authority (RHA) of Central for T2DMP (ICPC-2 – T90 classification) of Baixo Mondego and Dão Lafões, Portuguese NHS Primary Care Units clusters, medicated in 2017 with SGLT2i and re-studied in 2022, for closest date to the end of the year. Two values of HbA1c were taken as control cut-offs: ≤7% and ≤8%.

Results: A sample of n=264, 59.0% (n=156) male was studied. From 2017 to 2022: HbA1c, 7.62±1.21 to 7.56±1.12 (∆=-0.8) (p=0.951); BMI, 31.65±8.72 to 29.90±4.56 (∆=-5.5) (p<0.001); and AP, 104.90±13.64 to 105.58± 11.11(∆=+0.6) (p=0.424). The prevalence of controlled PMD2 under 65 years for HbA1c ≤7% in 2017 was 34.0% and in 2022 of 32.1%, ∆=-5.50; and for HbA1c ≤8% for older ones than 65 years of 74.8% in 2017 and of 743.3% in 2022, ∆=-0.02.

Discussion: Comparing these values with previous ones, an improvement in HbA1c and BMI, and worsening of AP was verified, sarcopenia possibly reducing BMI not balanced by the AP increase.

Conclusion: The effectiveness of iSGLT2 in the reduction of HbA1c and BMI was verified, unlike the AP and the frequency of controlled PDM2.

Downloads

Download data is not yet available.

Author Biography

  • Luiz Miguel Santiago, Faculdade de Medicina da Universidade de Coimbra Clínica Universitária de Medicina Geral e Familiar da Faculdade de Medicina da Universidade de Coimbra USF Topázio, ACES Baixo Mondego

    Luiz Miguel de Mendonça Soares Santiago é Licenciado em Medicina pela Universidade de Coimbra desde 1979, Mestre em Saúde Pública pela Universidade de Coimbra desde 2006 e Doutorado por unanimidade com distinção e louvor, pela Universidade de Coimbra, na Especialidade de Sociologia Médica, ramo de Medicina Preventiva e Comunitária desde 11/11/2009.

    É desde1/7/2017 Professor Associado da Faculdade de Medicina da Universidade de Coimbra, regendo as Unidades Curriculares de MISP IV, 3º Ano e de Medicina Geral e Familiar, 5º Ano.

    Desde 30 de Janeiro de 2018 tem o título de "Agregado".

    Médico, especialista em Medicina Geral e Familiar, é Consultor com o Grau de Assistente Graduado Sénior da Carreira de Medicina Geral e Familiar desde 2002, sendo orientador no Internato Complementar de Medicina Geral e Familiar desde 2006, tendo exercido na Unidade de Saúde Familiar Topázio em Coimbra, onde ainda continua actividade clínica, agora reduzida.

    Professor Associado Convidado da Universidade da Beira Interior, onde é regente das cadeiras de CSP I, II e III entre 2011 e 2017.

    Desde 2014 até 2017 foi Professor Adjunto Convidado da Coimbra Health Scholl lecionando Patologia Geral.   

    Membro da Academia Europeia de Professores em Medicina Geral e Familiar (EURACT) é orientador de Teses de Mestrado Integrado e de Mestrado Pré-Bolonha bem como de Doutoramento, na Universidade de Coimbra (2) e na Universidade da Beira Interior (6).

    É membro da Comissão de Ética da ARS do Centro.

    Tem vasta bibliografia publicada individualmente e em co-autoria em revistas nacionais e internacionais com “revisores-par” e indexadas (27 artigos).

    Desde março de 2017 é membro investigador do CEISUC, FEUC.

    Em Novembro de 2017 é eleito sócio correspondente da Academia Nacional de Medicina.

    Aguarda a marcação de Provas de Agregação a serem prestadas na Universidade da Beira Interior.

References

World Health Organization. Improving diabetes outcomes for all, a hundred years on from the discovery of insulin: report of the Global Diabetes Summit co-hosted by the World Health Organization and the Government of Canada [homepage]. Geneva: WHO; 2021. Available from: https://www.who.int/publications/i/item/9789240038943

Cho NH, Shaw JE, Karuranga S, Huang Y, Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81.

Raposo JF. Diabetes: factos e números 2016, 2017 e 2018. Rev Port Diabetes. 2020;15(1):19-27.

International Diabetes Federation. IDF diabetes atlas [homepage]. 10th ed. IDF; 2021. Available from: https://diabetesatlas.org/atlas/tenth-edition/

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S19-40.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140-57.

Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15(17):2565-85.

Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;25(8):1987.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.

European Medicines Agency. SGLT2 inhibitors: referral [homepage]. Amsterdam: EMA; 2016 Feb. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S97-110.

Portaria n.º 212/2017, de 19 de julho. Diário da República. I Série;(138).

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57.

Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):e007165.

Lima Jr JC, Moura-Assis A, Cintra RM, Quinaglia T, Velloso LA, Sposito AC. Central role of obesity in endothelial cell dysfunction and cardiovascular risk. Rev Assoc Med Bras. 2019;65(1):87-97.

Sociedade Portuguesa de Diabetologia. Tratamento da diabetes tipo 2 [homepage]. Lisboa: SPD; [s.d.]. Available from: https://guidelines.spd.pt/#/

American Diabetes Association. Understanding type 2 diabetes [homepage]. Arlington: ADA; [s.d.]. Available from: https://diabetes.org/diabetes/type-2

Pinto MM. Diabetes: the influence of pharmacological treatment in disease control and underlying obesity [dissertation]. Coimbra: Faculdade de Medicina da Universidade de Coimbra; 2022. Available from: https://estudogeral.sib.uc.pt/handle/10316/102412

Prazeres F, Santiago LM. Prevalence of multimorbidity in the adult population attending primary care in Portugal: a cross-sectional study. BMJ Open. 2015;25(9):e009287.

Simões PA, Santiago LM, Maurício K, Simões JA. Prevalence of potentially inappropriate medication in the older adult population within primary care in Portugal: a nationwide cross-sectional study. Patient Prefer Adherence. 2019;13:1569-76.

Downloads

Published

2024-02-28

Issue

Vol. 40 No. 1 (2024): Revista Portuguesa de Medicina Geral e Familiar

Section

Original Research

License

Copyright (c) 2024 Portuguese Journal of Family Medicine and General Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.

The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.

 

How to Cite

SGLT2 inhibitors for type 2 diabetes: how efficient are they in the analytic and anthropometric control?. (2024). Portuguese Journal of Family Medicine and General Practice, 40(1), 41-7. https://doi.org/10.32385/rpmgf.v40i1.13769

Most read articles by the same author(s)

1 2 3 4 5 6 > >>